by Madaline Spencer | Jun 5, 2026
The US Food and Drug Administration (FDA) has approved Cavhanza (nilotinib) orally disintegrating tablets for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). CML is a myeloproliferative neoplasm characterized by the expression of...
by Madaline Spencer | Jun 5, 2026
James Howard Jr., MD, Professor of Neurology at the University of North Carolina at Chapel Hill, discusses results from the ADAPT SERON clinical trial of efgartigimod IV in patients with seronegative generalized myasthenia gravis (gMG). Data from this trial was...
by Madaline Spencer | Jun 4, 2026
Michael Levy, MD, PhD, Neuroimmunologist and Associate Professor at Harvard Medical School, discusses results from the METEOROID clinical trial of Enspryng (satralizumab) in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). ...
by Madaline Spencer | Jun 3, 2026
The US Food and Drug Administration (FDA) has approved pivekimab sunirine-pvzy for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare, aggressive CD4+ CD56+ myeloid cancer characterized by cutaneous lesions, bone marrow involvement, and...
by Madaline Spencer | Jun 3, 2026
Sumaira Ahmed, Founder and Executive Director of The Sumaira Foundation, discusses her organization and the BEST-NMOSD clinical trial for patients with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare autoimmune disorder that...
